DRG Market Assessment reports

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…

Clarivate Epidemiology’s coverage of persistent depressive disorder comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

The rapid growth of digital therapeutic (DTx) solutions to treat medical problems, fueled by increased demand for telehealth services amid the COVID-19 pandemic, has tasked U.S. payers and pharmacy…

Opioid addiction is a chronic disease, generally driven by a strong and irresistible urge or craving for the intake of opioid drugs and an inability to stop despite negative consequences to health…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Clarivate Epidemiology’s coverage of attention-deficit/hyperactivity disorder (ADHD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…